litlas
Log inCreate account

Patricia LoRusso

Active 1995–2025

199
Papers
29,522
Citations
91
h-index
188
i10-index

Citations

Citations per year for Patricia LoRusso1997: 1 citations1998: 3 citations1999: 4 citations2000: 9 citations2001: 14 citations2002: 30 citations2003: 64 citations2004: 80 citations2005: 100 citations2006: 103 citations2007: 101 citations2008: 104 citations2009: 106 citations2010: 204 citations2011: 214 citations2012: 261 citations2013: 336 citations2014: 380 citations2015: 380 citations2016: 378 citations2017: 385 citations2018: 353 citations2019: 1,094 citations2020: 1,171 citations2021: 1,145 citations2022: 975 citations2023: 802 citations2024: 1,250 citations2025: 870 citations2026: 28 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,365 citing papers, 28.6% of this breakdownChina: 1,811 citing papers, 11.9% of this breakdownUnited Kingdom: 903 citing papers, 5.9% of this breakdownItaly: 812 citing papers, 5.3% of this breakdownGermany: 704 citing papers, 4.6% of this breakdownFrance: 610 citing papers, 4% of this breakdownCanada: 493 citing papers, 3.2% of this breakdownSpain: 487 citing papers, 3.2% of this breakdownJapan: 433 citing papers, 2.8% of this breakdownAustralia: 420 citing papers, 2.8% of this breakdownNetherlands: 357 citing papers, 2.3% of this breakdownSwitzerland: 351 citing papers, 2.3% of this breakdown
0%28.6%Other 23.1%

Institutions

Fields

  • Medicine53.2%
  • Biochemistry, Genetics and Molecular Biology32.1%
  • Immunology and Microbiology4.8%
  • Materials Science4.4%
  • Engineering1.2%
  • Neuroscience1.1%
  • Other3.2%

Topics

  • Cancer Immunotherapy and Biomarkers4%
  • HER2/EGFR in Cancer Research3.8%
  • Lung Cancer Treatments and Mutations2.9%
  • Monoclonal and Polyclonal Antibodies Research2.4%
  • Nanoparticle-Based Drug Delivery2.1%
  • RNA Interference and Gene Delivery2%
  • Other82.8%

Coauthors

All papers

Open in search
  1. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

    Authors: Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, Wilson H. Miller, Elena Garralda, Martin Förster, Armando Santoro, Alejandro Falcón, Tae Won Kim, Luis Paz‐Ares, Samantha Bowyer, Maria de Miguel, Sae‐Won Han, Matthew Krebs, Jong Seok Lee, Michael L. Cheng, Kathryn C. Arbour, Erminia Massarelli, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T. Lin, Stephanie Royer‐Joo, Julie Chang, Neekesh V. Dharia, Jennifer L. Schutzman, Jayesh Desai - New England Journal of Medicine 2023 cited by 294

  2. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Authors: Jayesh Desai, Guzmán Alonso, Se Hyun Kim, Andrés Cervantes, Thomas B. Karasic, Laura Medina, Einat Shacham‐Shmueli, Rasha Cosman, Alejandro Falcón, Eelke Gort, Tormod Kyrre Guren, Erminia Massarelli, Wilson H. Miller, Luis Paz‐Ares, Hans Prenen, Alessio Amatu, Chiara Cremolini, Tae Won Kim, Víctor Moreno, Sai‐Hong Ignatius Ou, Alessandro Passardi, Adrian G. Sacher, Armando Santoro, Rafał Stec, Susanna V. Ulahannan, Kathryn C. Arbour, Patricia LoRusso, Jia Luo, Manish R. Patel, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T. Lin, Stephanie Royer‐Joo, Julie Chang, Tomi Jun, Neekesh V. Dharia, Jennifer L. Schutzman, GO42144 Investigator and Study Group, Sae-Won Han - Nature Medicine 2023 cited by 122

  3. The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development

    Authors: Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, Patricia LoRusso, Elisabeth G.E. de Vries - Cancer Discovery 2024 cited by 186

  4. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Authors: Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, Patricia LoRusso, Jean-­Marc Ferrero, Tanja Badovinac-Črnjević, Silke Hoersch, Melanie C. Smitt, Hans Wildiers - The Lancet Oncology 2017 cited by 523

  5. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors

    Authors: Patricia LoRusso - Journal of Clinical Oncology 2016 cited by 489

  6. BET inhibitors: a novel epigenetic approach

    Authors: Deborah B. Doroshow, J.P. Eder, Patricia LoRusso - Annals of Oncology 2017 cited by 367

  7. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

    Authors: Johanna C. Bendell, Patricia LoRusso, Michael J. Overman, Anne M. Noonan, Dong‐Wan Kim, John H. Strickler, Sang‐We Kim, Stephen Clarke, Thomas J. George, Peter Grimison, Minal Barve, Manik Amin, Jayesh Desai, Trisha M. Wise‐Draper, Steven Eck, Yu Jiang, Anis A. Khan, Yuling Wu, Philip Martin, Zachary A. Cooper, Nairouz Elgeioushi, Nancy K. Mueller, Rakesh Kumar, Sandip Pravin Patel - Cancer Immunology Immunotherapy 2023 cited by 109

  8. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

    Authors: Nehal J. Lakhani, Laura Q.M. Chow, Justin F. Gainor, Patricia LoRusso, Keun‐Wook Lee, Hyun Cheol Chung, Jeeyun Lee, Yung‐Jue Bang, F. Stephen Hodi, Won Seog Kim, Rafael Santana-Dávila, Philip Fanning, Pierre Squifflet, Feng Jin, Tracy C. Kuo, Hong Wan, Jaume Pons, Sophia Randolph, Wells A. Messersmith - The Lancet Oncology 2021 cited by 127

  9. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

    Authors: Irene Braña, Antonio Calles, Patricia LoRusso, Lorrin Yee, Thomas A. Puchalski, Shobha Seetharam, Bob Zhong, Carla J. de Boer, Josep Tabernero, Emiliano Calvo - Targeted Oncology 2014 cited by 210

  10. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

    Authors: Alexander Muik, Elena Garralda, Işıl Altıntaş, Friederike Gieseke, Ravit Geva, Eytan Ben‐Ami, Corinne Maurice‐Dror, Emiliano Calvo, Patricia LoRusso, Guzmán Alonso, María E. Rodríguez-Ruiz, Kristina B. Schoedel, Jordan M. Blum, Bianca Sänger, Theodora W. Salcedo, Saskia M. Burm, Eliana Stanganello, Dennis Verzijl, Fulvia Vascotto, Angelica Sette, Juliane Quinkhardt, Theo S. Plantinga, Aras Toker, Edward N. van den Brink, Mark Fereshteh, Mustafa Diken, David Satijn, Sebastian Kreiter, Esther C.W. Breij, Gaurav Bajaj, Eleni Lagkadinou, Kate Sasser, Özlem Türeci, Ulf Forssmann, Tahamtan Ahmadi, Uğur Şahin, Maria Jure‐Kunkel, Ignacio Melero - Cancer Discovery 2022 cited by 113

  11. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

    Authors: Jeffrey S. Hrkach, Daniel D. Von Hoff, Mir Mukkaram Ali, Elizaveta A. Andrianova, Jason Auer, Tarikh Campbell, David De Witt, Michael Figa, Maria J. Figueiredo, Allen Horhota, Susan C. Low, Kevin McDonnell, Erick Peeke, Beadle Retnarajan, Abhimanyu Sabnis, Edward F. Schnipper, Jeffrey Song, Young Ho Song, Jason M. Summa, Douglas Tompsett, Greg Troiano, Tina Van Geen Hoven, Jim Wright, Patricia LoRusso, Philip W. Kantoff, Neil H. Bander, Christopher Sweeney, Omid C. Farokhzad, Róbert Langer, Stephen E. Zale - Science Translational Medicine 2012 cited by 1,119

  12. First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Authors: Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso, Andrés Cervantes, Gary K. Schwartz, Glen J. Weiss, Luis Paz‐Ares, Daniel C. Cho, Jeffrey R. Infante, María Alsina, Mrinal M. Gounder, Rick Falzone, Jamie Harrop, Amy C. Seila White, Iva Toudjarska, David Bumcrot, Rachel Meyers, Gregory Hinkle, Nenad Svrzikapa, Renta Hutabarat, Valerie A. Clausen, Jeffrey Cehelsky, Saraswathy V. Nochur, Christina Gamba‐Vitalo, Akshay Vaishnaw, Dinah W.Y. Sah, Jared Gollob, Howard A. Burris - Cancer Discovery 2013 cited by 699

  13. The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

    Authors: Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer, Junxian Geng, Teffany Davenport, Michael Teufel, Jian Li, Mehdi Lahmar, Mrinal M. Gounder - Cancer Discovery 2023 cited by 92

  14. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

    Authors: Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, Patricia LoRusso, Jean-­Marc Ferrero, Melanie C. Smitt, Ron Yu, Abraham C.F. Leung, Hans Wildiers - The Lancet Oncology 2014 cited by 716

  15. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

    Authors: Tae Won Kim, Philippe L. Bédard, Patricia LoRusso, Michael S. Gordon, Johanna C. Bendell, Do‐Youn Oh, Myung‐Ju Ahn, Elena Garralda, Sandra P. D’Angelo, Jayesh Desai, F. Stephen Hodi, Zev A. Wainberg, Jean‐Pierre Delord, Phillippe A. Cassier, Andrés Cervantes, Marta Gil-Martín, Benjamin Wu, Namrata S. Patil, Yanling Jin, Tien Hoang, Diana Mendus, Xiaohui Wen, Raymond D. Meng, Byoung Chul Cho - JAMA Oncology 2023 cited by 63

  16. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

    Authors: Helen Lee, Anthony F. Shields, Barry A. Siegel, Kathy D. Miller, Ian E. Krop, X. Cynthia, Patricia LoRusso, Pamela N. Münster, Karen Campbell, Daniel F. Gaddy, Shannon C. Leonard, Elena Geretti, Stephanie J. Blocker, Dmitri B. Kirpotin, Victor Moyo, Thomas J. Wickham, Bart S. Hendriks - Clinical Cancer Research 2017 cited by 368

  17. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

    Authors: Kyung Hae Jung, Patricia LoRusso, Howard A. Burris, Michael A. Gordon, Yung‐Jue Bang, Matthew D. Hellmann, Andrés Cervantes, María Ochoa de Olza, Aurélien Marabelle, F. Stephen Hodi, Myung‐Ju Ahn, Leisha A. Emens, Fabrice Barlési, Omid Hamid, Emiliano Calvo, David F. McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Lew Tsuhako, Kari M. Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis - Clinical Cancer Research 2019 cited by 286

  18. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

    Authors: Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L. Siu, Patricia LoRusso, Claire F. Friedman, Ani Sarkis Balmanoukian, Michael Gordon, Jeffrey Yachnin, Sylvie Rottey, Ioannis Karydis, George A. Fisher, Marcus Schmidt, Martin Schüler, Ryan J. Sullivan, Howard A. Burris, Vladimir Galvao, Brian S. Henick, Luc Dirix, Dirk Jaeger, Patrick A. Ott, Kit Man Wong, Guy Jérusalem, Aglaia Schiza, Lawrence Fong, Neeltje Steeghs, Rom S. Leidner, Achim Rittmeyer, Scott A. Laurie, Eelke Gort, Raid Aljumaily, Ignacio Melero, Rachel Lubong Sabado, Ina Rhee, Michael R. Mancuso, Lars Müller, Gregg Fine, Mahesh Yadav, Leesun Kim, Vincent J. P. Leveque, Alberto Robert, Martine Darwish, Ting Qi, Jiawen Zhu, Jingbin Zhang, Patrick Twomey, Gautham K. Rao, Donald W. Low, Christoph Petry, Amy A. Lo, Jill Schartner, Lélia Delamarre, Ira Mellman, Martin Löwer, Felicitas Müller, Evelyna Derhovanessian, Andrea Cortini, Luisa Manning, Daniel Maurus, Sebastian Brachtendorf, Verena Lörks, Tana Omokoko, Eva Godehardt, Dirk Becker, Christine Hawner, Christine Wallrapp, Christian Albrecht, Christoph Kröner, Arbel D. Tadmor, Jan Diekmann, Mathias Vormehr, Anette Jork, Anna Paruzynski, Maren Lang, Jonathon Blake, Oliver Hennig, Andreas N. Kuhn, Uğur Şahin, Özlem Türeci, D. Ross Camidge - Nature Medicine 2025 cited by 96

  19. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

    Authors: Mrinal M. Gounder, Todd M. Bauer, Gary K. Schwartz, Amy Weise, Patricia LoRusso, Prasanna Kumar, Ben Tao, Ying Hong, Parul Patel, Yasong Lu, Arnaud Lesegretain, Vijaya G. Tirunagaru, Feng Xu, Robert C. Doebele, David S. Hong - Journal of Clinical Oncology 2023 cited by 91

  20. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

    Authors: Joseph McLaughlin, Gang Han, Kurt A. Schalper, Daniel Carvajal‐Hausdorf, Vasiliki Pelekanou, Jamaal Rehman, Vamsidhar Velcheti, Roy S. Herbst, Patricia LoRusso, David L. Rimm - JAMA Oncology 2015 cited by 839

  21. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

    Authors: Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García, Fabrice André, Jean‐Pierre Delord, Manuel Hidalgo, Jan H.M. Schellens, Philippe A. Cassier, D. Ross Camidge, Martin Schüler, Ulka N. Vaishampayan, Howard A. Burris, Guangming Tian, Mario Campone, Zev A. Wainberg, Wan‐Teck Lim, Patricia LoRusso, Geoffrey I. Shapiro, Katie Parker, Xueying Chen, Somesh Choudhury, François Ringeisen, Diana Graus-Porta, Dale Porter, Randi Isaacs, Reinhard Buettner, Jürgen Wolf - Journal of Clinical Oncology 2017 cited by 435

  22. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

    Authors: Johnique T. Atkins, Goldy C. George, Kenneth R. Hess, Kathrina L. Marcelo-Lewis, Ying Yuan, Gautam Borthakur, Sean Khozin, Patricia LoRusso, David S. Hong - British Journal of Cancer 2020 cited by 120

  23. Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

    Authors: Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, Joyce F. Liu - Clinical Cancer Research 2022 cited by 63

  24. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

    Authors: Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jiménez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey - Clinical Cancer Research 2022 cited by 97